https://scholars.lib.ntu.edu.tw/handle/123456789/638435
標題: | A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors | 作者: | Chan, Stephen L Schuler, Martin Kang, Yoon-Koo Yen, Chia-Jui Edeline, Julien Choo, Su Pin CHIA-CHI LIN Okusaka, Takuji Weiss, Karl-Heinz Macarulla, Teresa Cattan, Stéphane Blanc, Jean-Frederic Lee, Kyung-Hun Maur, Michela Pant, Shubham Kudo, Masatoshi Assenat, Eric Zhu, Andrew X Yau, Thomas Lim, Ho Yeong Bruix, Jordi Geier, Andreas Guillén-Ponce, Carmen Fasolo, Angelica Finn, Richard S Fan, Jia Vogel, Arndt Qin, Shukui Riester, Markus Katsanou, Vasiliki Chaudhari, Monica Kakizume, Tomoyuki Gu, Yi Porta, Diana Graus Myers, Andrea Delord, Jean-Pierre |
關鍵字: | FGF19; FGFR4; Hepatocellular carcinoma; Immune checkpoint inhibitors; KLB; PD-1; PD-L1; Phase 1 | 公開日期: | 2-六月-2022 | 卷: | 41 | 期: | 1 | 來源出版物: | Journal of experimental & clinical cancer research : CR | 摘要: | Deregulation of FGF19-FGFR4 signaling is found in several cancers, including hepatocellular carcinoma (HCC), nominating it for therapeutic targeting. FGF401 is a potent, selective FGFR4 inhibitor with antitumor activity in preclinical models. This study was designed to determine the recommended phase 2 dose (RP2D), characterize PK/PD, and evaluate the safety and efficacy of FGF401 alone and combined with the anti-PD-1 antibody, spartalizumab. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/638435 | ISSN: | 1756-9966 | DOI: | 10.1186/s13046-022-02383-5 |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。